S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Did You See These Trend Reversals? (Ad)pixel
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Did You See These Trend Reversals? (Ad)pixel
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Did You See These Trend Reversals? (Ad)pixel
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Credit Suisse takeover hits heart of Swiss banking, identity
Did You See These Trend Reversals? (Ad)pixel
Small areas reopen near Fukushima nuclear plant, few return
'War of the states': EV, chip makers lavished with subsidies
What’s At Stake In April is Shocking (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
NYSE:RMD

ResMed - RMD Stock Forecast, Price & News

$218.99
+3.04 (+1.41%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$217.17
$219.52
50-Day Range
$205.86
$236.53
52-Week Range
$189.40
$253.67
Volume
512,223 shs
Average Volume
590,141 shs
Market Capitalization
$32.17 billion
P/E Ratio
39.74
Dividend Yield
0.80%
Price Target
$263.17

ResMed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
20.2% Upside
$263.17 Price Target
Short Interest
Healthy
0.89% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.39mentions of ResMed in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$6.60 M Sold Last Quarter
Proj. Earnings Growth
12.70%
From $6.38 to $7.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

162nd out of 996 stocks

Surgical & Medical Instruments Industry

12th out of 104 stocks


RMD stock logo

About ResMed (NYSE:RMD) Stock

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Stock News Headlines

This Tech Stock Could be the Next Amazon
You can learn its name in Luke Lango’s latest report, 5 Hypergrowth Stocks for 2023. Claim Your Free Report Here. pixel
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.
ResMed (RMD) Gains on Product Uptake Even as Expenses Rise
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Company Calendar

Last Earnings
1/26/2023
Ex-Dividend for 3/16 Dividend
2/08/2023
Dividend Payable
3/16/2023
Today
4/01/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
8,160
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$263.17
High Stock Price Forecast
$280.00
Low Stock Price Forecast
$245.00
Forecasted Upside/Downside
+20.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$779.44 million
Pretax Margin
26.57%

Debt

Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$7.32 per share
Book Value
$22.97 per share

Miscellaneous

Free Float
144,867,000
Market Cap
$32.17 billion
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Mick Farrell
    Chairman & Chief Executive Officer
  • Rob Douglas
    President & Chief Operating Officer
  • Brett A. SandercockBrett A. Sandercock
    Chief Financial Officer
  • Carlos M. Nunez
    Chief Medical Officer
  • Urvashi Tyagi
    Chief Technology Officer













RMD Stock - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price forecast for 2023?

8 equities research analysts have issued 12-month price objectives for ResMed's stock. Their RMD share price forecasts range from $245.00 to $280.00. On average, they expect the company's stock price to reach $263.17 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2023?

ResMed's stock was trading at $208.13 at the beginning of the year. Since then, RMD stock has increased by 5.2% and is now trading at $218.99.
View the best growth stocks for 2023 here
.

Are investors shorting ResMed?

ResMed saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,300,000 shares, an increase of 20.4% from the February 28th total of 1,080,000 shares. Based on an average trading volume of 653,000 shares, the short-interest ratio is currently 2.0 days. Approximately 0.9% of the company's stock are sold short.
View ResMed's Short Interest
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its quarterly earnings results on Thursday, January, 26th. The medical equipment provider reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.04. The medical equipment provider had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $996.22 million. ResMed had a net margin of 21.51% and a trailing twelve-month return on equity of 25.46%. ResMed's revenue was up 15.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.47 EPS.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, January 26th. Stockholders of record on Thursday, February 9th will be paid a dividend of $0.44 per share on Thursday, March 16th. This represents a $1.76 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Wednesday, February 8th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.76 per share and currently has a dividend yield of 0.82%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.94%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $218.99.

How much money does ResMed make?

ResMed (NYSE:RMD) has a market capitalization of $32.17 billion and generates $3.58 billion in revenue each year. The medical equipment provider earns $779.44 million in net income (profit) each year or $5.51 on an earnings per share basis.

How many employees does ResMed have?

The company employs 8,160 workers across the globe.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.

This page (NYSE:RMD) was last updated on 4/2/2023 by MarketBeat.com Staff